Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) Profit After Tax: 2013-2024

Historic Profit After Tax for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $31.9 million.

  • CytomX Therapeutics' Profit After Tax fell 348.06% to -$14.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.0 million, marking a year-over-year increase of 102.59%. This contributed to the annual value of $31.9 million for FY2024, which is 5700.88% up from last year.
  • CytomX Therapeutics' Profit After Tax amounted to $31.9 million in FY2024, which was up 5,700.88% from -$569,000 recorded in FY2023.
  • CytomX Therapeutics' Profit After Tax's 5-year high stood at $31.9 million during FY2024, with a 5-year trough of -$115.9 million in FY2021.
  • Moreover, its 3-year median value for Profit After Tax was -$569,000 (2023), whereas its average is -$22.7 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 78.76% in 2021, then skyrocketed by 5,700.88% in 2024.
  • Over the past 5 years, CytomX Therapeutics' Profit After Tax (Yearly) stood at -$64.8 million in 2020, then plummeted by 78.76% to -$115.9 million in 2021, then increased by 14.29% to -$99.3 million in 2022, then skyrocketed by 99.43% to -$569,000 in 2023, then skyrocketed by 5,700.88% to $31.9 million in 2024.